Glenmark Pharmaceuticals’ subsidiary, Glenmark Specialty SA, and Cosmo Pharmaceuticals NV have entered a distribution and license agreement for Winlevi (clascoterone cream 1%) in Europe and South Africa. This exclusive agreement covers 15 European Union countries, the UK, and South Africa. Cosmo’s subsidiary, Cassiopea, will manage the Centralized Marketing Authorization process at the European Medicines Agency. Glenmark will be responsible for product registration in the UK and South Africa. Winlevi, an FDA-approved topical treatment for acne, has gained popularity in the United States, becoming the most prescribed branded topical acne medication among healthcare providers in dermatology (88% market share as of June 2023). This collaboration enhances Glenmark’s dermatology portfolio in Europe.